Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint (NASDAQ: EYPT) will report its third quarter 2025 financial results on November 5, 2025 and will host a conference call and live webcast at 8:30 a.m. ET.
Investors can register for the live audio conference via the provided audio conference link and access a live audio webcast and replay through the company's Investors section at www.eyepointpharma.com.
EyePoint (NASDAQ: EYPT) granted inducement non‑statutory stock options to three new employees to purchase an aggregate of 13,500 shares, effective October 15, 2025, in accordance with NASDAQ Listing Rule 5635(c)(4).
The options carry an exercise price of $11.73 (closing price on October 15, 2025), a 10‑year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service. Grants were approved by the Compensation Committee as inducements for new hires.
EyePoint (NASDAQ: EYPT) priced an underwritten public offering on Oct 14, 2025 of 11,000,000 common shares at $12.00 per share and pre-funded warrants to purchase up to 1,500,000 shares at $11.999 each.
The aggregate gross proceeds are expected to be approximately $150 million before underwriting discounts, with closing expected on or about Oct 16, 2025. EyePoint granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. Net proceeds are intended to fund clinical development of DURAVYU for wet AMD and DME, earlier-stage pipeline work, and general corporate purposes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a proposed underwritten public offering of $150.0 million of common stock with a 30‑day underwriter option to purchase up to an additional $22.5 million. The company said proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier‑stage pipeline programs, and for general corporate purposes. J.P. Morgan, Jefferies, Citigroup, and Guggenheim are joint book‑running managers. The offering is subject to market conditions and will be made via a prospectus supplement to an effective Form S‑3 registration statement.
EyePoint (Nasdaq: EYPT) announced initiation of pivotal Phase 3 trials for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME), with first patient dosing anticipated in Q1 2026. The FDA-aligned program comprises two identical non-inferiority trials (COMO and CAPRI), each enrolling approximately 240 patients and comparing DURAVYU 2.7mg to on-label aflibercept 2mg, with redosing every six months.
Primary endpoint is change in BCVA blended at weeks 52 and 56. New preclinical data show vorolanib inhibits VEGFRs and JAK receptors, reducing IL-6 activity by >50% in vitro and supporting prior Phase 2 VERONA six-month efficacy signals and sustained six-month delivery from a single dose.
EyePoint Pharmaceuticals (Nasdaq: EYPT), a retinal disease therapeutics company, has granted inducement stock options to eight new employees outside of its 2023 Long-Term Incentive Plan. The grants, approved on September 15, 2025, include options to purchase up to 140,600 shares at an exercise price of $13.41 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.
EyePoint Pharmaceuticals (NASDAQ:EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three major upcoming investor conferences in September 2025.
The company will participate in fireside chats at Citi's 2025 BioPharma Back to School Conference on September 2 at 2:30 p.m. ET and the Cantor Global Healthcare Conference on September 3 at 2:45 p.m. ET. Additionally, management will conduct one-on-one investor meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. Webcasts of the presentations will be available on EyePoint's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a retinal disease therapeutics company, has granted inducement stock options to two new employees outside its 2023 Long-Term Incentive Plan. The grants, approved on August 15, 2025, include options to purchase up to 18,000 shares at an exercise price of $11.09 per share.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments over three years, subject to continued employment.
EyePoint Pharmaceuticals (NASDAQ:EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Dr. Jay S. Duker, President and CEO, will engage in a fireside chat on August 13, 2025, at 10:00 a.m. ET.
Investors can access the live webcast through the company's website, with a replay available for 90 days following the event.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2025 financial results and significant progress in its DURAVYU™ development program for wet AMD. The company successfully completed enrollment for two Phase 3 trials: LUGANO (432 U.S. patients) and LUCIA (over 400 global patients), both achieving unprecedented seven-month enrollment periods.
Q2 2025 financial results showed revenue of $5.3 million, down from $9.5 million in Q2 2024. The company reported a net loss of $59.4 million ($0.85 per share). EyePoint maintains a strong financial position with $256 million in cash, providing runway into 2027, beyond the expected Phase 3 topline data readouts in mid-2026.
The company's Northbridge, MA manufacturing facility is now operational and producing DURAVYU registration batches in preparation for potential FDA approval.